NCT02569996View on ClinicalTrials.gov

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Lymphoma, Follicular
Interventions
DRUG

Rituximab

Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.

Trial Locations (21)

1071

Budapest

1083

Budapest

1085

Budapest

1088

Budapest

1122

Budapest

1135

Budapest

2800

Tatabánya

3529

Miskolc

4032

Debrecen

4400

Nyíregyháza

5004

Szolnok

5700

Gyula

6720

Szeged

7100

Szekszárd

7400

Kaposvár

7624

Pécs

8000

Székesfehérvár

8200

Veszprém

8900

Zalaegerszeg

9024

Győr

9700

Szombathely

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02569996 - A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | Biotech Hunter | Biotech Hunter